Crescent Biopharma, Inc. (CBIO)
| Market Cap | 893.69M +245.5% |
| Revenue (ttm) | 11.88M |
| Net Income | -165.12M |
| EPS | -6.03 |
| Shares Out | 42.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 239,696 |
| Open | 20.09 |
| Previous Close | 20.88 |
| Day's Range | 20.09 - 21.53 |
| 52-Week Range | 8.72 - 27.41 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 30.60 (+46.55%) |
| Earnings Date | Jul 30, 2026 |
About CBIO
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is head... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CBIO stock is "Strong Buy." The 12-month stock price target is $30.6, which is an increase of 46.55% from the latest price.
News
Crescent Biopharma to Present at September Investor Conferences
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next...
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma reports Q2 EPS (74c), consensus (64c)
“We have continued to demonstrate exceptional execution and are on track for multiple key clinical data readouts across our portfolio in 2027. The positive momentum in our ASCEND trial of…
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-00...
Crescent Biopharma Earnings release: Q2 2026
Crescent Biopharma released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Crescent Biopharma Quarterly report: Q2 2026
Crescent Biopharma has published its Q2 2026 quarterly earnings report on July 30, 2026.
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma 8.095M share Spot Secondary priced at $14.50
Jefferies, TD Cowen, Guggenheim and Cantor Fitzgerald acted as joint book running managers for the offering.
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma files ordinary shares offering, no amount given
Jefferies, TD Cowen, Guggenheim, and Cantor are acting as joint book-running managers. LifeSci Capital is acting as a book-running manager.
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma Registration statement: Registration filing
Crescent Biopharma filed a registration statement on July 1, 2026, providing details about a securities offering with the SEC.
Crescent Biopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The session highlighted a robust oncology pipeline with CR-001 as a potential next-generation backbone therapy, supported by innovative ADC combinations and a strong partnership with Kelun-Biotech. Key data readouts are expected in 2027, with a financial runway into 2028 and a focus on rapid, data-driven expansion across major cancer indications.
Crescent Biopharma Transcript: Jefferies Global Healthcare Conference 2026
HARMONi-6 and related data validate PD-1/VEGF bispecifics as a new backbone in immuno-oncology, showing strong efficacy and safety across tumor types. Strategic trial design, global considerations, and robust partnerships, especially with Kelun-Biotech, are driving pipeline expansion and positioning for leadership in the field.
Crescent Biopharma to Present at June Investor Conferences
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma Transcript: AGM 2026
The meeting confirmed the election of two directors, ratified the auditor, and approved executive compensation and annual advisory votes on compensation. No shareholder questions were raised, and final vote results will be published in the minutes and Form 8-K.
Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Crescent Biopharma (CBIO) to Neutral from Buy without a price target saying the ivonescimab copycat thesis is less compelling after Merck and Kelun’s sacituzumab tirumotecan...
Crescent Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
The summit highlighted a robust oncology pipeline with four clinical studies launching this year, focusing on next-gen IO bispecifics and ADCs. Key data readouts are expected in 2027, leveraging strategic partnerships and a matrix portfolio approach to target multiple solid tumors and drive future development.
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multip...
Crescent Biopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum
The company is advancing a next-generation oncology portfolio with a focus on synergistic IO and ADC combinations, supported by a key partnership with Kelun. Comprehensive global trials and upcoming data readouts in 2027 will guide indication selection and registration strategies, with a strong financial position enabling execution.
Crescent Biopharma Transcript: Bank of America Global Healthcare Conference 2026
The team is advancing a dual strategy in oncology with a next-gen bispecific and ADC portfolio, targeting robust data readouts by 2027. Global trials and a key partnership with Kelun-Biotech are accelerating development and supporting broad indication coverage.
Crescent Biopharma to Present at May Investor Conferences
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next w...
Crescent Biopharma reports Q1 EPS (70c), consensus (79c)
Reports Q1 revenue $1.04M, consensus $357,140. “Crescent’s execution on the advancement of our pipeline this quarter positions us for meaningful clinical data readouts in 2027 from CR-001, our potenti...
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination...
Crescent Biopharma Quarterly report: Q1 2026
Crescent Biopharma has published its Q1 2026 quarterly earnings report on April 29, 2026.